[닫기]
잠시만 기다려 주세요. 로딩중입니다.

당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제

Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist

Journal of Korean Diabetes 2019년 20권 3호 p.149 ~ 156
이인국 ( Lee In-Kuk ) - 연세대학교 의과대학 내과학교실

강은석 ( Kang Eun-Seok ) - 연세대학교 의과대학 내과학교실

Abstract


According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.

키워드

Cardiovascular diseases; Diabetes mellitus; Glucagon-like peptide-1; Kidney diseases; Obesity
원문 및 링크아웃 정보
등재저널 정보